SCHEMBL6399197

SCHEMBL6399197

CC(C(=O)c1cc(O)ccc1P(=O)(O)O)c1cccc(O)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.40
CYP3A4 P08684 2/20 0.40
MEN1 O00255 1/20 0.40
PPARG P37231 1/20 0.40
KMT2A Q03164 1/20 0.40
HIF1A Q16665 4/20 0.39
LMNA P02545 3/20 0.39
KDM4E B2RXH2 3/20 0.39
ADRB1 P08588 2/20 0.39
ADRA1A P35348 2/20 0.39
MIF P14174 1/20 0.39
HTR2A P28223 1/20 0.39
HTR2B P41595 1/20 0.39
AKR1C3 P42330 1/20 0.36
AKR1C2 P52895 1/20 0.36
ESR1 P03372 1/20 0.34
ESR2 Q92731 1/20 0.34
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6396095 0.89 MAPT (0.43) MAPTCYP3A4MEN1PPARGKMT2A
SCHEMBL6398706 0.87 CYP3A4 (0.49) MAPTCYP3A4MEN1PPARGKMT2A
SCHEMBL6402080 0.83 LMNA (0.45) HIF1ALMNAKDM4EADRB1ADRA1A
SCHEMBL6394698 0.80 HIF1A (0.36) HIF1ALMNAKDM4EADRB1ADRA1A
SCHEMBL6399194 0.80 MAPT (0.38) MAPTCYP3A4MEN1PPARGKMT2A
SCHEMBL6401957 0.80 MEN1 (0.40) MAPTCYP3A4MEN1PPARGKMT2A
SCHEMBL6399888 0.80 KDM4E (0.38) MAPTCYP3A4MEN1PPARGKMT2A
SCHEMBL6396815 0.78 HIF1A (0.37) MAPTCYP3A4MEN1PPARGKMT2A
SCHEMBL6396090 0.77 MAPT (0.40) MAPTCYP3A4MEN1PPARGKMT2A
SCHEMBL6396423 0.77 MEN1 (0.43) MAPTCYP3A4MEN1PPARGKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans PEERCE BRIAN E (US) 2005-08-25 US disclosed
US-6787528-B2 THERAPY FOR KIDNEY DISEASES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2004-09-07 US disclosed
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2003-08-28 US disclosed
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation PEERCE BRIAN E (US) 2002-09-19 US disclosed
US-6355823-B1 MEMBRANE SUBSTRATE PHOSPHATED FOR DRUGS FOR GASTROINTESTINAL DISORDERS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2002-03-12 US disclosed
EP-1175425-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2002-01-30 EP disclosed
WO-2000043402-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2000-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 MAPT 3461/4885CYP3A4 1053/4885MEN1 1773/4885
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation SLC10A2, SLC34A3, SLC34A1 MAPT 3363/4885CYP3A4 1301/4885MEN1 2179/4885
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 MAPT 3461/4885CYP3A4 1053/4885MEN1 1773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.